Mike Egan serves as the Vice President of Neuroscience at Merck, where he leads global clinical development. His expertise spans psychiatry, drug development, and translational medicine, backed by a residency at the University of Colorado and a fellowship at the National Institute of Mental Health.
His research on the genetic effects of COMT on human cognition and schizophrenia was cited by Science in 2003 as a runner-up for "Breakthrough of the Year. "
Mike Egan
Vice President, Neuroscience, Global Clinical Develpment at Merck
Villanova, Pennsylvania, United States
Overview
Topics They Care About
Neuroscience Drug Development
Leads global clinical development in neuroscience at Merck, focusing on advancing new treatments for psychiatric and neurological disorders.
Psychiatric Genetics
As a principal investigator at NIMH, he discovered the genetic effects of several genes on cognition and the risk for schizophrenia.
Translational Medicine
His career focuses on applying insights from genetic research and psychopharmacology to the development of new therapeutics.
Media Appearances
Mike has no verified media appearances
Work History
1-2018
Vice President, Neuroscience, Global Clinical Develpment at Merck
3-2015
Associate Vice President, Clinical Neuroscience at Merck
7-2012 - 3-2015
Executive Director at Merck
2005 - 2012
Senior Medical Director at Merck Research Laboratories
1998 - 2005
Principle Investigator at NIMH
1996 - 1998
Acting Branch Chief at National Institute of Mental Health
Education
1987 - 1994
Fellowship from National Institute of Mental Health
1983 - 1987
Residency from University of Colorado Anschutz
More Information
Social Presence :
Prographics :
Exp : 30
Location : Villanova, Pennsylvania, United States
Job Level : Senior
Designation : Vice President, Neuroscience, Global Clinical Develpment at Merck
